Barry Uretsky
Concepts (770)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 97 | 2024 | 328 | 21.490 |
Why?
| | Coronary Occlusion | 58 | 2023 | 80 | 12.440 |
Why?
| | Coronary Artery Disease | 41 | 2024 | 320 | 11.990 |
Why?
| | Fractional Flow Reserve, Myocardial | 39 | 2023 | 127 | 11.190 |
Why?
| | Angioplasty, Balloon, Coronary | 55 | 2020 | 175 | 10.490 |
Why?
| | Coronary Angiography | 114 | 2023 | 386 | 8.440 |
Why?
| | Stents | 54 | 2023 | 372 | 8.390 |
Why?
| | Coronary Vessels | 37 | 2024 | 172 | 7.490 |
Why?
| | Coronary Stenosis | 22 | 2021 | 99 | 6.060 |
Why?
| | Myocardial Infarction | 52 | 2024 | 448 | 5.070 |
Why?
| | Drug-Eluting Stents | 22 | 2023 | 101 | 4.750 |
Why?
| | Treatment Outcome | 128 | 2024 | 5475 | 4.480 |
Why?
| | Cardiac Catheterization | 33 | 2023 | 241 | 3.910 |
Why?
| | Coronary Artery Bypass | 19 | 2022 | 136 | 2.960 |
Why?
| | Humans | 324 | 2024 | 52546 | 2.820 |
Why?
| | Heart Failure | 53 | 2021 | 579 | 2.800 |
Why?
| | Acute Coronary Syndrome | 8 | 2022 | 106 | 2.710 |
Why?
| | Chronic Disease | 55 | 2023 | 588 | 2.350 |
Why?
| | Tomography, Optical Coherence | 8 | 2018 | 108 | 2.230 |
Why?
| | Coronary Disease | 26 | 2015 | 164 | 2.150 |
Why?
| | Saphenous Vein | 14 | 2021 | 65 | 2.140 |
Why?
| | Risk Factors | 76 | 2023 | 3950 | 2.050 |
Why?
| | Graft Occlusion, Vascular | 13 | 2021 | 78 | 2.040 |
Why?
| | Coronary Thrombosis | 9 | 2020 | 23 | 1.980 |
Why?
| | Platelet Aggregation Inhibitors | 12 | 2014 | 212 | 1.980 |
Why?
| | Male | 186 | 2024 | 26808 | 1.900 |
Why?
| | Myocardial Ischemia | 13 | 2020 | 132 | 1.740 |
Why?
| | Cardiology | 14 | 2019 | 100 | 1.720 |
Why?
| | Predictive Value of Tests | 27 | 2023 | 946 | 1.720 |
Why?
| | Aged | 103 | 2023 | 10200 | 1.680 |
Why?
| | Registries | 33 | 2023 | 633 | 1.670 |
Why?
| | Middle Aged | 141 | 2024 | 13091 | 1.660 |
Why?
| | Thrombosis | 11 | 2018 | 260 | 1.630 |
Why?
| | Coronary Restenosis | 8 | 2021 | 39 | 1.620 |
Why?
| | Myocardium | 20 | 2013 | 478 | 1.540 |
Why?
| | Time Factors | 53 | 2023 | 2990 | 1.540 |
Why?
| | Heptanoic Acids | 15 | 2008 | 35 | 1.480 |
Why?
| | Pyrroles | 15 | 2008 | 72 | 1.440 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 13 | 2022 | 147 | 1.370 |
Why?
| | Risk Assessment | 30 | 2023 | 1348 | 1.350 |
Why?
| | Heart Injuries | 3 | 2019 | 16 | 1.310 |
Why?
| | Female | 140 | 2024 | 28214 | 1.280 |
Why?
| | Cardiac Tamponade | 4 | 2024 | 29 | 1.230 |
Why?
| | Cardiotonic Agents | 23 | 2019 | 85 | 1.230 |
Why?
| | Ventricular Function, Left | 16 | 2023 | 177 | 1.220 |
Why?
| | Myocardial Reperfusion Injury | 10 | 2011 | 53 | 1.180 |
Why?
| | Hemodynamics | 38 | 2018 | 265 | 1.110 |
Why?
| | Postoperative Complications | 17 | 2019 | 1080 | 1.100 |
Why?
| | Collateral Circulation | 10 | 2020 | 38 | 1.090 |
Why?
| | Vasodilator Agents | 8 | 2016 | 93 | 1.060 |
Why?
| | Coronary Circulation | 11 | 2024 | 57 | 1.020 |
Why?
| | Societies, Medical | 10 | 2019 | 202 | 1.000 |
Why?
| | Heart-Assist Devices | 4 | 2020 | 155 | 0.990 |
Why?
| | Heart Transplantation | 28 | 2009 | 344 | 0.970 |
Why?
| | Contrast Media | 9 | 2018 | 173 | 0.950 |
Why?
| | Ventricular Dysfunction, Left | 8 | 2018 | 108 | 0.920 |
Why?
| | Prosthesis Design | 11 | 2021 | 260 | 0.920 |
Why?
| | Cardiac Catheters | 4 | 2020 | 12 | 0.920 |
Why?
| | Thrombolytic Therapy | 2 | 2020 | 113 | 0.910 |
Why?
| | Death, Sudden, Cardiac | 6 | 2008 | 60 | 0.870 |
Why?
| | Pericarditis | 2 | 2022 | 20 | 0.870 |
Why?
| | Balloon Occlusion | 1 | 2024 | 17 | 0.850 |
Why?
| | Adenosine | 7 | 2018 | 72 | 0.840 |
Why?
| | Algorithms | 6 | 2021 | 669 | 0.840 |
Why?
| | Pericardial Effusion | 1 | 2024 | 39 | 0.830 |
Why?
| | Hemorrhage | 4 | 2019 | 224 | 0.820 |
Why?
| | Digitalis | 2 | 2021 | 5 | 0.810 |
Why?
| | Cardiovascular Agents | 5 | 2009 | 65 | 0.800 |
Why?
| | Occupational Health | 1 | 2023 | 66 | 0.780 |
Why?
| | Aneurysm, False | 5 | 2020 | 43 | 0.780 |
Why?
| | Pericarditis, Constrictive | 1 | 2022 | 2 | 0.780 |
Why?
| | Aorta | 4 | 2019 | 170 | 0.750 |
Why?
| | Retrospective Studies | 31 | 2020 | 6644 | 0.730 |
Why?
| | Hypotension, Controlled | 1 | 2021 | 3 | 0.730 |
Why?
| | Radiography, Interventional | 7 | 2018 | 58 | 0.730 |
Why?
| | Anemia | 1 | 2022 | 75 | 0.720 |
Why?
| | Angina, Unstable | 8 | 2016 | 31 | 0.700 |
Why?
| | Thrombocytopenia | 1 | 2022 | 91 | 0.700 |
Why?
| | Mammary Arteries | 3 | 2017 | 10 | 0.690 |
Why?
| | Absorbable Implants | 2 | 2022 | 13 | 0.690 |
Why?
| | Follow-Up Studies | 27 | 2019 | 2290 | 0.690 |
Why?
| | Prognosis | 19 | 2023 | 2113 | 0.680 |
Why?
| | Inferior Wall Myocardial Infarction | 1 | 2020 | 1 | 0.670 |
Why?
| | Thiazolidinediones | 6 | 2008 | 83 | 0.660 |
Why?
| | Time-to-Treatment | 2 | 2020 | 79 | 0.650 |
Why?
| | Shock, Cardiogenic | 1 | 2020 | 34 | 0.650 |
Why?
| | Digoxin | 11 | 2021 | 29 | 0.640 |
Why?
| | Cardiovascular Diseases | 11 | 2015 | 494 | 0.630 |
Why?
| | Prospective Studies | 28 | 2023 | 2450 | 0.630 |
Why?
| | Diabetic Angiopathies | 2 | 2013 | 24 | 0.630 |
Why?
| | Stroke Volume | 18 | 2023 | 160 | 0.620 |
Why?
| | Enbucrilate | 1 | 2019 | 6 | 0.620 |
Why?
| | Tissue Adhesives | 1 | 2019 | 15 | 0.620 |
Why?
| | Heart Ventricles | 8 | 2012 | 267 | 0.620 |
Why?
| | Arterial Pressure | 1 | 2019 | 44 | 0.620 |
Why?
| | Hyperemia | 3 | 2016 | 17 | 0.620 |
Why?
| | Pericardium | 4 | 2022 | 29 | 0.620 |
Why?
| | Practice Guidelines as Topic | 3 | 2020 | 498 | 0.610 |
Why?
| | Operative Time | 3 | 2019 | 77 | 0.600 |
Why?
| | Guideline Adherence | 1 | 2020 | 143 | 0.600 |
Why?
| | Adrenergic beta-Antagonists | 5 | 2008 | 112 | 0.590 |
Why?
| | Aspirin | 5 | 2022 | 122 | 0.580 |
Why?
| | Troponin T | 3 | 2011 | 12 | 0.570 |
Why?
| | Hematoma | 2 | 2013 | 68 | 0.570 |
Why?
| | Severity of Illness Index | 19 | 2019 | 1038 | 0.560 |
Why?
| | Electrocardiography | 15 | 2022 | 280 | 0.560 |
Why?
| | Heart Septum | 3 | 2010 | 22 | 0.560 |
Why?
| | Hydrostatic Pressure | 1 | 2017 | 7 | 0.550 |
Why?
| | Angioplasty, Balloon | 4 | 2022 | 70 | 0.540 |
Why?
| | Perioperative Care | 5 | 2015 | 43 | 0.540 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 10 | 2011 | 82 | 0.530 |
Why?
| | Creatine Kinase, MB Form | 3 | 2013 | 10 | 0.530 |
Why?
| | Defibrillators, Implantable | 5 | 2007 | 67 | 0.520 |
Why?
| | Surgical Procedures, Operative | 4 | 2015 | 64 | 0.520 |
Why?
| | Foramen Ovale, Patent | 2 | 2014 | 31 | 0.520 |
Why?
| | Purinergic P2Y Receptor Antagonists | 2 | 2014 | 35 | 0.500 |
Why?
| | United States | 27 | 2022 | 5225 | 0.490 |
Why?
| | Propranolol | 3 | 2008 | 78 | 0.490 |
Why?
| | Kidney Failure, Chronic | 4 | 2004 | 215 | 0.490 |
Why?
| | Heart | 10 | 2006 | 360 | 0.480 |
Why?
| | Randomized Controlled Trials as Topic | 12 | 2021 | 613 | 0.480 |
Why?
| | Veterans | 1 | 2022 | 581 | 0.480 |
Why?
| | Tissue Donors | 2 | 2013 | 124 | 0.470 |
Why?
| | Alloys | 2 | 2020 | 9 | 0.470 |
Why?
| | Incidence | 16 | 2018 | 1077 | 0.470 |
Why?
| | Heart Rupture, Post-Infarction | 3 | 2005 | 5 | 0.460 |
Why?
| | Aortic Valve | 3 | 2022 | 126 | 0.460 |
Why?
| | Physician-Patient Relations | 2 | 2015 | 144 | 0.460 |
Why?
| | Fibrinolytic Agents | 3 | 2014 | 132 | 0.450 |
Why?
| | Tomography, X-Ray Computed | 5 | 2013 | 1162 | 0.450 |
Why?
| | Vascular System Injuries | 1 | 2015 | 38 | 0.450 |
Why?
| | Wounds, Penetrating | 1 | 2015 | 39 | 0.450 |
Why?
| | Ultrasonography, Interventional | 7 | 2013 | 139 | 0.440 |
Why?
| | Purines | 2 | 2014 | 33 | 0.430 |
Why?
| | Adenosine A2 Receptor Agonists | 1 | 2014 | 5 | 0.430 |
Why?
| | Lisinopril | 7 | 2003 | 13 | 0.430 |
Why?
| | Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 2009 | 46 | 0.430 |
Why?
| | Anterior Wall Myocardial Infarction | 2 | 2012 | 7 | 0.420 |
Why?
| | Clinical Trials as Topic | 9 | 2012 | 471 | 0.420 |
Why?
| | Computer-Assisted Instruction | 1 | 2014 | 30 | 0.420 |
Why?
| | Metals | 2 | 2011 | 37 | 0.420 |
Why?
| | Cyclooxygenase 2 | 8 | 2008 | 50 | 0.410 |
Why?
| | Piperazines | 2 | 2012 | 125 | 0.410 |
Why?
| | Blood Vessel Prosthesis Implantation | 4 | 2009 | 122 | 0.410 |
Why?
| | Pyrazoles | 2 | 2014 | 113 | 0.410 |
Why?
| | Anticholesteremic Agents | 3 | 2008 | 31 | 0.410 |
Why?
| | Mentors | 1 | 2014 | 56 | 0.410 |
Why?
| | Coronary Vessel Anomalies | 3 | 2017 | 37 | 0.410 |
Why?
| | Arteries | 1 | 2013 | 93 | 0.410 |
Why?
| | Atrial Function, Left | 1 | 2013 | 5 | 0.400 |
Why?
| | Endarterectomy, Carotid | 2 | 2011 | 62 | 0.400 |
Why?
| | Lipoxins | 3 | 2008 | 3 | 0.400 |
Why?
| | Imidazoles | 9 | 1990 | 124 | 0.400 |
Why?
| | Drug Administration Schedule | 7 | 2014 | 374 | 0.390 |
Why?
| | Cardiac Surgical Procedures | 3 | 2014 | 325 | 0.390 |
Why?
| | Coronary Aneurysm | 2 | 2007 | 19 | 0.390 |
Why?
| | Rats, Sprague-Dawley | 14 | 2008 | 1544 | 0.390 |
Why?
| | Pressure | 4 | 2017 | 103 | 0.390 |
Why?
| | Rats | 19 | 2011 | 3182 | 0.380 |
Why?
| | Drug Eruptions | 1 | 2012 | 14 | 0.380 |
Why?
| | Physicians | 2 | 2015 | 240 | 0.380 |
Why?
| | Thiophenes | 1 | 2012 | 46 | 0.380 |
Why?
| | Stroke | 3 | 2013 | 516 | 0.370 |
Why?
| | Embolism | 2 | 2013 | 18 | 0.370 |
Why?
| | Quality Assurance, Health Care | 4 | 2012 | 149 | 0.370 |
Why?
| | Cyclooxygenase Inhibitors | 5 | 2007 | 39 | 0.360 |
Why?
| | Double-Blind Method | 14 | 2020 | 719 | 0.360 |
Why?
| | Internet | 1 | 2014 | 261 | 0.360 |
Why?
| | Diverticulum | 1 | 2011 | 21 | 0.360 |
Why?
| | Intraoperative Complications | 4 | 2020 | 113 | 0.350 |
Why?
| | Troponin I | 1 | 2011 | 19 | 0.350 |
Why?
| | Transurethral Resection of Prostate | 1 | 2011 | 10 | 0.350 |
Why?
| | Carotid Arteries | 1 | 2011 | 76 | 0.350 |
Why?
| | Receptors, Adrenergic, beta-2 | 2 | 2009 | 16 | 0.340 |
Why?
| | Embolic Protection Devices | 1 | 2010 | 7 | 0.340 |
Why?
| | Clinical Competence | 4 | 2013 | 399 | 0.340 |
Why?
| | Myocytes, Cardiac | 5 | 2011 | 145 | 0.340 |
Why?
| | Paclitaxel | 1 | 2011 | 89 | 0.340 |
Why?
| | Receptors, Opioid, delta | 2 | 2009 | 25 | 0.340 |
Why?
| | Pericardiectomy | 2 | 2024 | 6 | 0.330 |
Why?
| | Mitral Valve | 1 | 2010 | 56 | 0.330 |
Why?
| | Endocarditis | 1 | 2010 | 31 | 0.330 |
Why?
| | Kaplan-Meier Estimate | 6 | 2017 | 483 | 0.320 |
Why?
| | Calcinosis | 4 | 2023 | 52 | 0.310 |
Why?
| | Anticoagulants | 6 | 2024 | 277 | 0.310 |
Why?
| | Suction | 2 | 2008 | 23 | 0.310 |
Why?
| | Echocardiography, Transesophageal | 2 | 2006 | 60 | 0.300 |
Why?
| | Sirolimus | 2 | 2009 | 72 | 0.300 |
Why?
| | Adult | 44 | 2019 | 14168 | 0.300 |
Why?
| | Hypoglycemic Agents | 3 | 2006 | 217 | 0.300 |
Why?
| | Carotid Artery, Common | 2 | 2006 | 44 | 0.290 |
Why?
| | Heart Valve Prosthesis | 3 | 2022 | 89 | 0.290 |
Why?
| | Myocardial Bridging | 1 | 2008 | 2 | 0.290 |
Why?
| | Tissue Plasminogen Activator | 1 | 2009 | 109 | 0.290 |
Why?
| | Heart Failure, Systolic | 1 | 2008 | 7 | 0.290 |
Why?
| | Aortic Valve Stenosis | 3 | 2022 | 78 | 0.290 |
Why?
| | Peptides | 2 | 2008 | 236 | 0.280 |
Why?
| | Azetidines | 1 | 2008 | 6 | 0.280 |
Why?
| | Creatinine | 3 | 2004 | 159 | 0.280 |
Why?
| | Patient Selection | 7 | 2012 | 266 | 0.280 |
Why?
| | Consensus | 2 | 2007 | 192 | 0.280 |
Why?
| | Exercise Test | 10 | 2002 | 144 | 0.280 |
Why?
| | Heart Septal Defects, Atrial | 2 | 2013 | 44 | 0.270 |
Why?
| | Cardiac Output, Low | 4 | 2006 | 12 | 0.270 |
Why?
| | Telemedicine | 1 | 2014 | 493 | 0.270 |
Why?
| | Animals | 28 | 2022 | 13464 | 0.270 |
Why?
| | Vascular Patency | 5 | 2020 | 82 | 0.270 |
Why?
| | Laboratories, Hospital | 1 | 2006 | 6 | 0.260 |
Why?
| | Survival Analysis | 11 | 2010 | 671 | 0.260 |
Why?
| | Mitral Valve Insufficiency | 3 | 2007 | 55 | 0.260 |
Why?
| | Aortic Valve Insufficiency | 2 | 2016 | 26 | 0.260 |
Why?
| | Terminology as Topic | 3 | 2013 | 71 | 0.260 |
Why?
| | Echocardiography, Three-Dimensional | 1 | 2006 | 15 | 0.250 |
Why?
| | Drug Therapy, Combination | 9 | 2008 | 399 | 0.250 |
Why?
| | Chi-Square Distribution | 3 | 2017 | 294 | 0.250 |
Why?
| | Pacemaker, Artificial | 1 | 2007 | 42 | 0.250 |
Why?
| | Proportional Hazards Models | 8 | 2017 | 444 | 0.250 |
Why?
| | Bacteremia | 1 | 2007 | 90 | 0.240 |
Why?
| | Gadolinium DTPA | 1 | 2005 | 26 | 0.240 |
Why?
| | Inpatients | 2 | 2018 | 209 | 0.240 |
Why?
| | Chest Pain | 3 | 2006 | 58 | 0.240 |
Why?
| | Nitric Oxide Synthase Type III | 6 | 2008 | 83 | 0.230 |
Why?
| | Carotid Artery Diseases | 1 | 2005 | 31 | 0.230 |
Why?
| | Lipopolysaccharides | 1 | 2006 | 205 | 0.230 |
Why?
| | Calcium | 1 | 2007 | 374 | 0.230 |
Why?
| | Angina, Stable | 2 | 2016 | 7 | 0.230 |
Why?
| | Prostaglandins | 1 | 2005 | 21 | 0.230 |
Why?
| | Europe | 8 | 2019 | 91 | 0.230 |
Why?
| | Neovascularization, Physiologic | 2 | 2005 | 87 | 0.230 |
Why?
| | Program Evaluation | 1 | 2006 | 351 | 0.230 |
Why?
| | Pain Management | 3 | 2015 | 177 | 0.230 |
Why?
| | Atrial Fibrillation | 4 | 2021 | 201 | 0.220 |
Why?
| | Renal Insufficiency | 1 | 2005 | 114 | 0.220 |
Why?
| | Dose-Response Relationship, Drug | 12 | 2017 | 1372 | 0.220 |
Why?
| | Chemokine CCL2 | 1 | 2004 | 68 | 0.220 |
Why?
| | Metabolic Clearance Rate | 1 | 2004 | 67 | 0.220 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2004 | 7 | 0.220 |
Why?
| | Equipment Design | 4 | 2020 | 290 | 0.220 |
Why?
| | Angiography | 7 | 2012 | 115 | 0.220 |
Why?
| | History, 21st Century | 2 | 2019 | 59 | 0.220 |
Why?
| | Pericardiocentesis | 1 | 2024 | 16 | 0.220 |
Why?
| | Femoral Artery | 4 | 2019 | 107 | 0.210 |
Why?
| | Monocytes | 1 | 2004 | 129 | 0.210 |
Why?
| | History, 20th Century | 2 | 2019 | 96 | 0.210 |
Why?
| | Artifacts | 1 | 2004 | 55 | 0.210 |
Why?
| | Reoperation | 5 | 2013 | 464 | 0.210 |
Why?
| | Secondary Prevention | 2 | 2015 | 85 | 0.210 |
Why?
| | Arginine Vasopressin | 5 | 2005 | 10 | 0.210 |
Why?
| | Reproducibility of Results | 6 | 2016 | 1223 | 0.210 |
Why?
| | Staphylococcal Infections | 1 | 2007 | 280 | 0.210 |
Why?
| | Recurrence | 7 | 2016 | 683 | 0.210 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2004 | 34 | 0.210 |
Why?
| | Disease Models, Animal | 10 | 2011 | 1480 | 0.210 |
Why?
| | Angina Pectoris | 4 | 2020 | 20 | 0.210 |
Why?
| | Nitric Oxide Synthase Type II | 4 | 2008 | 63 | 0.200 |
Why?
| | Risk | 7 | 2011 | 313 | 0.200 |
Why?
| | Catheterization | 4 | 2019 | 96 | 0.200 |
Why?
| | Aged, 80 and over | 10 | 2017 | 3414 | 0.200 |
Why?
| | Materials Testing | 2 | 2020 | 55 | 0.200 |
Why?
| | American Heart Association | 4 | 2015 | 33 | 0.190 |
Why?
| | Hospital Mortality | 5 | 2019 | 459 | 0.190 |
Why?
| | Anti-Arrhythmia Agents | 4 | 2004 | 81 | 0.190 |
Why?
| | Cyclosporins | 5 | 1989 | 8 | 0.190 |
Why?
| | Body Composition | 1 | 2004 | 341 | 0.190 |
Why?
| | Vasodilation | 2 | 2021 | 101 | 0.190 |
Why?
| | Constriction, Pathologic | 3 | 2017 | 91 | 0.180 |
Why?
| | Odds Ratio | 4 | 2016 | 565 | 0.180 |
Why?
| | Exercise Tolerance | 5 | 1997 | 48 | 0.180 |
Why?
| | Propanolamines | 3 | 2011 | 14 | 0.180 |
Why?
| | Retreatment | 2 | 2012 | 58 | 0.170 |
Why?
| | Diet, Sodium-Restricted | 1 | 2000 | 5 | 0.170 |
Why?
| | Up-Regulation | 4 | 2011 | 462 | 0.170 |
Why?
| | Enalapril | 3 | 1989 | 15 | 0.170 |
Why?
| | Heart Valve Prosthesis Implantation | 2 | 2016 | 102 | 0.170 |
Why?
| | United States Department of Veterans Affairs | 1 | 2022 | 293 | 0.170 |
Why?
| | Logistic Models | 5 | 2018 | 932 | 0.170 |
Why?
| | Ischemia | 1 | 2021 | 154 | 0.160 |
Why?
| | Hospitalization | 5 | 2011 | 749 | 0.160 |
Why?
| | Angioplasty | 1 | 2020 | 21 | 0.160 |
Why?
| | Calcitonin Gene-Related Peptide | 2 | 2009 | 24 | 0.160 |
Why?
| | Administration, Oral | 8 | 2015 | 455 | 0.160 |
Why?
| | 6-Ketoprostaglandin F1 alpha | 3 | 2008 | 4 | 0.160 |
Why?
| | Life Style | 1 | 2000 | 146 | 0.160 |
Why?
| | Dobutamine | 5 | 1999 | 20 | 0.160 |
Why?
| | Plaque, Atherosclerotic | 1 | 2019 | 44 | 0.160 |
Why?
| | Heart Rate | 7 | 1993 | 318 | 0.150 |
Why?
| | Specialization | 1 | 2019 | 49 | 0.150 |
Why?
| | Atherectomy | 1 | 2019 | 13 | 0.150 |
Why?
| | Cost-Benefit Analysis | 2 | 2014 | 269 | 0.150 |
Why?
| | Atrial Natriuretic Factor | 4 | 1996 | 25 | 0.150 |
Why?
| | Russia | 4 | 2019 | 10 | 0.150 |
Why?
| | Quality Improvement | 2 | 2011 | 224 | 0.150 |
Why?
| | Radial Artery | 1 | 2019 | 34 | 0.150 |
Why?
| | Prevalence | 5 | 2018 | 1017 | 0.150 |
Why?
| | Peripheral Arterial Disease | 1 | 2019 | 77 | 0.150 |
Why?
| | Feasibility Studies | 2 | 2020 | 403 | 0.150 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2009 | 170 | 0.150 |
Why?
| | Catheterization, Peripheral | 1 | 2019 | 49 | 0.150 |
Why?
| | Patient Care Planning | 1 | 2019 | 68 | 0.140 |
Why?
| | Tachycardia, Ventricular | 2 | 2004 | 46 | 0.140 |
Why?
| | Cardiomyopathies | 8 | 2003 | 123 | 0.140 |
Why?
| | Patient Care | 1 | 1998 | 57 | 0.140 |
Why?
| | Emergency Medical Services | 1 | 2019 | 112 | 0.140 |
Why?
| | Patient Safety | 1 | 2018 | 103 | 0.140 |
Why?
| | Multivariate Analysis | 6 | 2016 | 602 | 0.140 |
Why?
| | Blood Pressure | 12 | 1997 | 537 | 0.140 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2004 | 568 | 0.140 |
Why?
| | Medicare | 2 | 2011 | 274 | 0.140 |
Why?
| | Fistula | 2 | 1996 | 27 | 0.140 |
Why?
| | Education, Medical | 1 | 2019 | 111 | 0.140 |
Why?
| | Waiting Lists | 3 | 2007 | 53 | 0.140 |
Why?
| | Adventitia | 1 | 2017 | 4 | 0.130 |
Why?
| | Curriculum | 3 | 2013 | 394 | 0.130 |
Why?
| | Education, Medical, Graduate | 3 | 2013 | 217 | 0.130 |
Why?
| | Cardiac Pacing, Artificial | 3 | 2008 | 34 | 0.130 |
Why?
| | Quality of Life | 5 | 2008 | 882 | 0.130 |
Why?
| | Enoximone | 9 | 1990 | 10 | 0.130 |
Why?
| | Advisory Committees | 2 | 2014 | 72 | 0.130 |
Why?
| | Myocardial Revascularization | 3 | 2012 | 30 | 0.130 |
Why?
| | Substance Withdrawal Syndrome | 2 | 1997 | 167 | 0.130 |
Why?
| | Epoprostenol | 4 | 1997 | 15 | 0.130 |
Why?
| | Hypertension, Pulmonary | 7 | 1997 | 118 | 0.130 |
Why?
| | Phosphorylation | 6 | 2008 | 525 | 0.130 |
Why?
| | Nitric Oxide Synthase | 2 | 2008 | 64 | 0.130 |
Why?
| | Simvastatin | 2 | 2008 | 27 | 0.120 |
Why?
| | Treatment Failure | 4 | 2018 | 122 | 0.120 |
Why?
| | Propensity Score | 1 | 2017 | 158 | 0.120 |
Why?
| | Hypertension | 6 | 2011 | 568 | 0.120 |
Why?
| | Health Personnel | 3 | 2007 | 252 | 0.120 |
Why?
| | Benzazepines | 2 | 2006 | 20 | 0.120 |
Why?
| | Phosphodiesterase Inhibitors | 4 | 2007 | 23 | 0.120 |
Why?
| | Magnetic Resonance Imaging | 1 | 2022 | 1536 | 0.120 |
Why?
| | Muscle Contraction | 1 | 1996 | 116 | 0.120 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2018 | 203 | 0.120 |
Why?
| | Postpericardiotomy Syndrome | 1 | 2015 | 4 | 0.120 |
Why?
| | Diagnostic Techniques, Cardiovascular | 2 | 2012 | 4 | 0.120 |
Why?
| | Age Factors | 5 | 2021 | 1131 | 0.110 |
Why?
| | Angioscopy | 1 | 1994 | 3 | 0.110 |
Why?
| | Cardiomyopathy, Dilated | 3 | 1996 | 38 | 0.110 |
Why?
| | Colchicine | 1 | 2015 | 24 | 0.110 |
Why?
| | Renin | 4 | 1996 | 18 | 0.110 |
Why?
| | Smad3 Protein | 1 | 2014 | 9 | 0.110 |
Why?
| | Norepinephrine | 5 | 1996 | 112 | 0.110 |
Why?
| | Systole | 4 | 2010 | 74 | 0.110 |
Why?
| | Cholesterol, Dietary | 1 | 2014 | 19 | 0.110 |
Why?
| | Th2 Cells | 1 | 2014 | 22 | 0.110 |
Why?
| | Tunica Intima | 1 | 1994 | 56 | 0.110 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 3 | 2011 | 50 | 0.110 |
Why?
| | Patient Care Management | 1 | 2014 | 18 | 0.110 |
Why?
| | Venous Thrombosis | 1 | 2015 | 90 | 0.110 |
Why?
| | Myocardial Contraction | 4 | 2009 | 112 | 0.110 |
Why?
| | Area Under Curve | 3 | 2022 | 183 | 0.110 |
Why?
| | Receptors, LDL | 1 | 2014 | 73 | 0.110 |
Why?
| | Acute Disease | 5 | 2019 | 387 | 0.110 |
Why?
| | Disease Progression | 5 | 2008 | 872 | 0.110 |
Why?
| | Punctures | 3 | 2019 | 55 | 0.110 |
Why?
| | Cardiovascular System | 1 | 2014 | 55 | 0.110 |
Why?
| | Thromboembolism | 1 | 2014 | 50 | 0.110 |
Why?
| | Atherosclerosis | 2 | 2014 | 225 | 0.110 |
Why?
| | Cohort Studies | 6 | 2022 | 1552 | 0.110 |
Why?
| | Diuretics | 4 | 1998 | 31 | 0.110 |
Why?
| | Dependovirus | 1 | 2014 | 103 | 0.110 |
Why?
| | Cardiac Output | 10 | 1997 | 41 | 0.100 |
Why?
| | Transfection | 1 | 2014 | 369 | 0.100 |
Why?
| | Survival Rate | 6 | 2018 | 949 | 0.100 |
Why?
| | Remote Consultation | 1 | 2014 | 29 | 0.100 |
Why?
| | Drug Costs | 1 | 2014 | 39 | 0.100 |
Why?
| | Quality Indicators, Health Care | 2 | 2011 | 91 | 0.100 |
Why?
| | Arrhythmias, Cardiac | 2 | 2012 | 98 | 0.100 |
Why?
| | Case-Control Studies | 3 | 2013 | 1198 | 0.100 |
Why?
| | Septal Occluder Device | 1 | 2013 | 36 | 0.100 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2013 | 21 | 0.100 |
Why?
| | Pulmonary Edema | 1 | 2013 | 15 | 0.100 |
Why?
| | Echocardiography, Doppler | 2 | 2016 | 55 | 0.100 |
Why?
| | Hypertrophy, Left Ventricular | 3 | 2009 | 43 | 0.100 |
Why?
| | General Surgery | 1 | 2014 | 105 | 0.100 |
Why?
| | Pulmonary Wedge Pressure | 7 | 1997 | 23 | 0.100 |
Why?
| | Heparin | 2 | 2024 | 87 | 0.100 |
Why?
| | Signal Transduction | 3 | 2009 | 1704 | 0.100 |
Why?
| | Evidence-Based Medicine | 2 | 2011 | 270 | 0.100 |
Why?
| | Cause of Death | 7 | 2007 | 163 | 0.100 |
Why?
| | Pleural Effusion | 1 | 2013 | 38 | 0.100 |
Why?
| | Ultrasonography | 3 | 2010 | 423 | 0.100 |
Why?
| | Graft Rejection | 8 | 2009 | 173 | 0.100 |
Why?
| | Echocardiography | 7 | 2005 | 415 | 0.100 |
Why?
| | Kidney Diseases | 2 | 2007 | 231 | 0.090 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2014 | 243 | 0.090 |
Why?
| | Infusions, Intravenous | 7 | 2011 | 220 | 0.090 |
Why?
| | Embolism, Cholesterol | 1 | 2011 | 2 | 0.090 |
Why?
| | Sex Factors | 5 | 2022 | 731 | 0.090 |
Why?
| | Creatine Kinase | 2 | 2003 | 32 | 0.090 |
Why?
| | Carbazoles | 2 | 2005 | 18 | 0.090 |
Why?
| | Cardiovascular Surgical Procedures | 2 | 2012 | 12 | 0.090 |
Why?
| | Random Allocation | 4 | 2005 | 289 | 0.090 |
Why?
| | Equipment Failure | 3 | 2008 | 64 | 0.090 |
Why?
| | Milrinone | 1 | 2011 | 7 | 0.090 |
Why?
| | Exercise | 1 | 1996 | 552 | 0.090 |
Why?
| | Isoenzymes | 2 | 2003 | 167 | 0.090 |
Why?
| | Insurance Claim Review | 1 | 2011 | 40 | 0.090 |
Why?
| | Death | 2 | 2022 | 23 | 0.090 |
Why?
| | Diabetes Complications | 3 | 2011 | 125 | 0.090 |
Why?
| | Enkephalin, D-Penicillamine (2,5)- | 2 | 2009 | 3 | 0.090 |
Why?
| | Unnecessary Procedures | 1 | 2011 | 20 | 0.090 |
Why?
| | Prednisone | 3 | 1989 | 102 | 0.090 |
Why?
| | Oxygen Consumption | 5 | 1996 | 201 | 0.080 |
Why?
| | Body Weight | 3 | 2007 | 526 | 0.080 |
Why?
| | Preoperative Care | 2 | 2007 | 174 | 0.080 |
Why?
| | Thrombectomy | 1 | 2011 | 73 | 0.080 |
Why?
| | Necrosis | 1 | 2010 | 170 | 0.080 |
Why?
| | Injections, Intra-Arterial | 2 | 2015 | 13 | 0.080 |
Why?
| | Cyclooxygenase 2 Inhibitors | 2 | 2007 | 22 | 0.080 |
Why?
| | Texas | 4 | 2006 | 141 | 0.080 |
Why?
| | Disease Management | 3 | 2014 | 186 | 0.080 |
Why?
| | Surgical Instruments | 1 | 2010 | 28 | 0.080 |
Why?
| | Cells, Cultured | 4 | 2009 | 1586 | 0.080 |
Why?
| | Reperfusion Injury | 2 | 2007 | 72 | 0.080 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2010 | 63 | 0.080 |
Why?
| | Diatrizoate | 1 | 1989 | 2 | 0.080 |
Why?
| | Iopamidol | 1 | 1989 | 2 | 0.080 |
Why?
| | Receptors, Calcitonin Gene-Related Peptide | 1 | 2009 | 4 | 0.080 |
Why?
| | Ethanolamines | 2 | 1986 | 10 | 0.080 |
Why?
| | ROC Curve | 2 | 2022 | 253 | 0.080 |
Why?
| | Hyperlipidemias | 2 | 2011 | 52 | 0.080 |
Why?
| | Endothelium, Vascular | 2 | 2007 | 257 | 0.070 |
Why?
| | Drug Administration Routes | 1 | 2008 | 10 | 0.070 |
Why?
| | Leukotriene B4 | 1 | 2008 | 1 | 0.070 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2008 | 3 | 0.070 |
Why?
| | Fatal Outcome | 2 | 2007 | 194 | 0.070 |
Why?
| | Hemostasis, Surgical | 1 | 2008 | 12 | 0.070 |
Why?
| | Phospholipases A | 2 | 2006 | 14 | 0.070 |
Why?
| | Phospholipases A2 | 2 | 2006 | 15 | 0.070 |
Why?
| | Comorbidity | 1 | 2010 | 631 | 0.070 |
Why?
| | Patient Transfer | 1 | 2009 | 99 | 0.070 |
Why?
| | Meta-Analysis as Topic | 1 | 2008 | 40 | 0.070 |
Why?
| | Analysis of Variance | 2 | 2008 | 557 | 0.070 |
Why?
| | Drainage | 1 | 2008 | 87 | 0.070 |
Why?
| | Sulfonamides | 2 | 2008 | 133 | 0.070 |
Why?
| | Kidney | 3 | 2005 | 722 | 0.070 |
Why?
| | Heart Diseases | 3 | 2006 | 223 | 0.070 |
Why?
| | Myocardial Reperfusion | 1 | 2007 | 13 | 0.070 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 638 | 0.070 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2007 | 49 | 0.070 |
Why?
| | Tetrazoles | 1 | 2007 | 41 | 0.070 |
Why?
| | Dipyridamole | 1 | 2007 | 7 | 0.070 |
Why?
| | Prosthesis Failure | 2 | 2012 | 113 | 0.070 |
Why?
| | Microinjections | 2 | 2018 | 36 | 0.070 |
Why?
| | Prostaglandin D2 | 1 | 2007 | 22 | 0.070 |
Why?
| | Cyclooxygenase 1 | 1 | 2007 | 7 | 0.070 |
Why?
| | Drug Interactions | 2 | 2007 | 202 | 0.070 |
Why?
| | Calcium Signaling | 1 | 2007 | 52 | 0.070 |
Why?
| | Nitroso Compounds | 1 | 2006 | 3 | 0.070 |
Why?
| | Patient Admission | 1 | 2007 | 80 | 0.070 |
Why?
| | Thoracic Surgery | 1 | 2007 | 22 | 0.060 |
Why?
| | Mass Screening | 2 | 2004 | 358 | 0.060 |
Why?
| | Enzyme Induction | 1 | 2006 | 76 | 0.060 |
Why?
| | Anemia, Macrocytic | 1 | 1986 | 2 | 0.060 |
Why?
| | Deferoxamine | 1 | 1986 | 9 | 0.060 |
Why?
| | Anemia, Megaloblastic | 1 | 1986 | 3 | 0.060 |
Why?
| | PPAR gamma | 1 | 2007 | 73 | 0.060 |
Why?
| | Biotin | 1 | 2006 | 46 | 0.060 |
Why?
| | Ubiquinone | 1 | 2006 | 14 | 0.060 |
Why?
| | NF-kappa B | 1 | 2008 | 329 | 0.060 |
Why?
| | Hemofiltration | 1 | 2006 | 8 | 0.060 |
Why?
| | Magnesium | 1 | 2006 | 32 | 0.060 |
Why?
| | Electric Countershock | 1 | 2006 | 30 | 0.060 |
Why?
| | Diagnosis, Differential | 2 | 2012 | 1044 | 0.060 |
Why?
| | Forecasting | 1 | 2007 | 154 | 0.060 |
Why?
| | Multicenter Studies as Topic | 4 | 2005 | 112 | 0.060 |
Why?
| | Patient Education as Topic | 2 | 2000 | 322 | 0.060 |
Why?
| | Intracranial Embolism | 1 | 2006 | 29 | 0.060 |
Why?
| | Radiology | 1 | 2008 | 134 | 0.060 |
Why?
| | Antihypertensive Agents | 2 | 1997 | 131 | 0.060 |
Why?
| | Heart Atria | 1 | 2006 | 64 | 0.060 |
Why?
| | Ischemic Preconditioning | 1 | 2005 | 6 | 0.060 |
Why?
| | Aortic Rupture | 1 | 2006 | 18 | 0.060 |
Why?
| | Triiodobenzoic Acids | 1 | 2005 | 9 | 0.060 |
Why?
| | Partnership Practice | 1 | 2005 | 1 | 0.060 |
Why?
| | Organizational Affiliation | 1 | 2005 | 2 | 0.060 |
Why?
| | Myocardial Stunning | 1 | 2005 | 2 | 0.060 |
Why?
| | Health Planning | 1 | 2005 | 13 | 0.060 |
Why?
| | Pyrrolidines | 1 | 2006 | 63 | 0.060 |
Why?
| | Metoprolol | 1 | 2005 | 13 | 0.060 |
Why?
| | Foreign Bodies | 1 | 2006 | 66 | 0.060 |
Why?
| | Device Removal | 1 | 2006 | 82 | 0.060 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 123 | 0.060 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2006 | 91 | 0.060 |
Why?
| | Iron | 1 | 1986 | 130 | 0.060 |
Why?
| | Aortic Coarctation | 1 | 2006 | 31 | 0.060 |
Why?
| | Sensitivity and Specificity | 3 | 2006 | 883 | 0.060 |
Why?
| | Accidents, Traffic | 1 | 2006 | 90 | 0.060 |
Why?
| | Isoxazoles | 1 | 2005 | 15 | 0.060 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2005 | 11 | 0.060 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 25 | 0.060 |
Why?
| | Education, Medical, Continuing | 1 | 2005 | 72 | 0.060 |
Why?
| | Water-Electrolyte Balance | 1 | 1985 | 30 | 0.060 |
Why?
| | Tetralogy of Fallot | 1 | 2006 | 83 | 0.060 |
Why?
| | Ephedrine | 1 | 2004 | 21 | 0.060 |
Why?
| | Regional Blood Flow | 1 | 2004 | 110 | 0.060 |
Why?
| | Leadership | 1 | 2005 | 105 | 0.060 |
Why?
| | Hyperhomocysteinemia | 1 | 2004 | 29 | 0.060 |
Why?
| | Body Surface Area | 1 | 2004 | 27 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2007 | 336 | 0.060 |
Why?
| | Polyethylene Terephthalates | 1 | 2004 | 10 | 0.060 |
Why?
| | Brachiocephalic Trunk | 1 | 2004 | 6 | 0.060 |
Why?
| | Antioxidants | 1 | 2006 | 257 | 0.050 |
Why?
| | Ventricular Remodeling | 1 | 2004 | 65 | 0.050 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2004 | 37 | 0.050 |
Why?
| | Abnormalities, Multiple | 1 | 2006 | 168 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2005 | 187 | 0.050 |
Why?
| | Injections, Intravenous | 4 | 2004 | 135 | 0.050 |
Why?
| | Arteriosclerosis | 1 | 2004 | 50 | 0.050 |
Why?
| | Swine Diseases | 1 | 2004 | 7 | 0.050 |
Why?
| | Myocarditis | 1 | 1984 | 48 | 0.050 |
Why?
| | Potassium Channels | 1 | 2004 | 32 | 0.050 |
Why?
| | Inflammation | 2 | 2007 | 643 | 0.050 |
Why?
| | Enoxaparin | 1 | 2024 | 31 | 0.050 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2004 | 35 | 0.050 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2005 | 191 | 0.050 |
Why?
| | Edema | 1 | 2004 | 65 | 0.050 |
Why?
| | Vasoconstrictor Agents | 1 | 2004 | 81 | 0.050 |
Why?
| | Immunohistochemistry | 2 | 2005 | 980 | 0.050 |
Why?
| | Radiography | 3 | 2006 | 474 | 0.050 |
Why?
| | Glomerular Filtration Rate | 2 | 2018 | 129 | 0.050 |
Why?
| | Staphylococcus aureus | 1 | 2007 | 331 | 0.050 |
Why?
| | Sample Size | 1 | 2003 | 49 | 0.050 |
Why?
| | Heart Aneurysm | 1 | 1983 | 13 | 0.050 |
Why?
| | Retroperitoneal Space | 1 | 2002 | 26 | 0.050 |
Why?
| | Internship and Residency | 1 | 2008 | 438 | 0.050 |
Why?
| | C-Reactive Protein | 1 | 2003 | 152 | 0.050 |
Why?
| | Methoxamine | 2 | 1993 | 4 | 0.050 |
Why?
| | Mitral Valve Prolapse | 1 | 1982 | 4 | 0.050 |
Why?
| | Drug Synergism | 3 | 2007 | 148 | 0.050 |
Why?
| | Morphine Derivatives | 1 | 2022 | 27 | 0.050 |
Why?
| | Anesthesia | 1 | 2002 | 66 | 0.050 |
Why?
| | Renal Dialysis | 1 | 2003 | 191 | 0.050 |
Why?
| | Pain Clinics | 1 | 2001 | 3 | 0.040 |
Why?
| | Hospital Units | 1 | 2001 | 11 | 0.040 |
Why?
| | Hospitals | 1 | 2022 | 184 | 0.040 |
Why?
| | Dogs | 3 | 1993 | 183 | 0.040 |
Why?
| | Benchmarking | 2 | 2011 | 64 | 0.040 |
Why?
| | Heart Arrest | 1 | 2002 | 136 | 0.040 |
Why?
| | Nitroglycerin | 3 | 2004 | 8 | 0.040 |
Why?
| | Comprehensive Health Care | 1 | 2000 | 9 | 0.040 |
Why?
| | Fluoroscopy | 2 | 1993 | 51 | 0.040 |
Why?
| | Autopsy | 1 | 2000 | 47 | 0.040 |
Why?
| | Cardiology Service, Hospital | 1 | 2000 | 15 | 0.040 |
Why?
| | Tissue Scaffolds | 1 | 2020 | 40 | 0.040 |
Why?
| | Arkansas | 2 | 2016 | 2026 | 0.040 |
Why?
| | Vitamins | 1 | 2000 | 65 | 0.040 |
Why?
| | Biocompatible Materials | 1 | 2020 | 65 | 0.040 |
Why?
| | Amyloidosis | 2 | 1991 | 85 | 0.040 |
Why?
| | Public Policy | 2 | 2012 | 38 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 2 | 2015 | 166 | 0.040 |
Why?
| | Diastole | 2 | 1993 | 68 | 0.040 |
Why?
| | Peripheral Vascular Diseases | 1 | 2000 | 23 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2004 | 809 | 0.040 |
Why?
| | Renal Artery Obstruction | 1 | 2000 | 21 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2000 | 463 | 0.040 |
Why?
| | Hospitals, Public | 1 | 1999 | 7 | 0.040 |
Why?
| | Placebos | 2 | 1990 | 85 | 0.040 |
Why?
| | Carotid Stenosis | 1 | 2000 | 66 | 0.040 |
Why?
| | Syndrome | 3 | 2006 | 252 | 0.040 |
Why?
| | Morbidity | 1 | 1999 | 141 | 0.040 |
Why?
| | Risk Adjustment | 1 | 2019 | 17 | 0.040 |
Why?
| | Adolescent | 7 | 1996 | 6713 | 0.040 |
Why?
| | Quality of Health Care | 1 | 2000 | 188 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2014 | 909 | 0.040 |
Why?
| | Injections, Intralesional | 1 | 2018 | 32 | 0.040 |
Why?
| | Internationality | 1 | 2018 | 46 | 0.040 |
Why?
| | Radiation Dosage | 1 | 2019 | 162 | 0.040 |
Why?
| | Patient Care Team | 1 | 2000 | 273 | 0.040 |
Why?
| | Drug Evaluation | 2 | 1995 | 25 | 0.040 |
Why?
| | Ventricular Pressure | 1 | 1997 | 16 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2018 | 73 | 0.030 |
Why?
| | Immunoblotting | 2 | 2008 | 119 | 0.030 |
Why?
| | Health Services Needs and Demand | 1 | 1999 | 159 | 0.030 |
Why?
| | Respiration | 2 | 1996 | 100 | 0.030 |
Why?
| | Internal Mammary-Coronary Artery Anastomosis | 1 | 1997 | 6 | 0.030 |
Why?
| | Calcium Channel Blockers | 1 | 1997 | 60 | 0.030 |
Why?
| | Radiation Monitoring | 1 | 2017 | 7 | 0.030 |
Why?
| | Biopsy | 5 | 1994 | 602 | 0.030 |
Why?
| | International Cooperation | 2 | 2007 | 52 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 236 | 0.030 |
Why?
| | Cardiomegaly | 2 | 1988 | 57 | 0.030 |
Why?
| | Patient Compliance | 1 | 1998 | 229 | 0.030 |
Why?
| | Ventricular Function, Right | 1 | 1997 | 40 | 0.030 |
Why?
| | Hormones | 2 | 1987 | 59 | 0.030 |
Why?
| | Isotonic Contraction | 1 | 1996 | 1 | 0.030 |
Why?
| | Isometric Contraction | 1 | 1996 | 21 | 0.030 |
Why?
| | Vascular Resistance | 3 | 1997 | 50 | 0.030 |
Why?
| | Forearm | 1 | 1996 | 31 | 0.030 |
Why?
| | Mice | 3 | 2014 | 5939 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 1998 | 606 | 0.030 |
Why?
| | Italy | 1 | 2015 | 26 | 0.030 |
Why?
| | Data Collection | 3 | 2011 | 290 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 1998 | 323 | 0.030 |
Why?
| | Carbon Dioxide | 1 | 1996 | 96 | 0.030 |
Why?
| | Blood Flow Velocity | 1 | 2015 | 95 | 0.030 |
Why?
| | Phlebography | 1 | 2015 | 55 | 0.030 |
Why?
| | Neurotransmitter Agents | 1 | 1995 | 34 | 0.030 |
Why?
| | Radionuclide Angiography | 1 | 1994 | 1 | 0.030 |
Why?
| | Tubulin Modulators | 1 | 2015 | 28 | 0.030 |
Why?
| | Atherectomy, Coronary | 1 | 1994 | 6 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2020 | 1680 | 0.030 |
Why?
| | Time | 1 | 2014 | 29 | 0.030 |
Why?
| | Journal Impact Factor | 1 | 2014 | 8 | 0.030 |
Why?
| | Kinetics | 2 | 1986 | 622 | 0.030 |
Why?
| | Genetic Vectors | 1 | 2014 | 130 | 0.030 |
Why?
| | Models, Cardiovascular | 2 | 2004 | 22 | 0.030 |
Why?
| | Nervous System Diseases | 1 | 1995 | 94 | 0.030 |
Why?
| | Fibrosis | 1 | 2014 | 197 | 0.030 |
Why?
| | Pulmonary Circulation | 1 | 1993 | 28 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 2014 | 123 | 0.030 |
Why?
| | Learning Curve | 1 | 2013 | 19 | 0.030 |
Why?
| | Drug Monitoring | 1 | 1993 | 82 | 0.030 |
Why?
| | Ultrasonics | 1 | 1993 | 26 | 0.030 |
Why?
| | Apoptosis | 2 | 2011 | 1121 | 0.030 |
Why?
| | Ischemic Attack, Transient | 1 | 2013 | 59 | 0.030 |
Why?
| | Jugular Veins | 1 | 1993 | 30 | 0.020 |
Why?
| | Cardiac Imaging Techniques | 1 | 2012 | 9 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 2008 | 1004 | 0.020 |
Why?
| | Alprostadil | 1 | 1992 | 10 | 0.020 |
Why?
| | Mice, Inbred C57BL | 2 | 2008 | 1898 | 0.020 |
Why?
| | Intra-Aortic Balloon Pumping | 1 | 1992 | 7 | 0.020 |
Why?
| | Tissue Survival | 1 | 2012 | 10 | 0.020 |
Why?
| | Smoking | 2 | 2011 | 517 | 0.020 |
Why?
| | Myocardial Perfusion Imaging | 1 | 2012 | 17 | 0.020 |
Why?
| | Obesity | 1 | 2000 | 1188 | 0.020 |
Why?
| | Endocardium | 2 | 1989 | 7 | 0.020 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2012 | 52 | 0.020 |
Why?
| | Phosphodiesterase 3 Inhibitors | 1 | 2011 | 1 | 0.020 |
Why?
| | Health Status | 1 | 1993 | 299 | 0.020 |
Why?
| | Adrenergic beta-1 Receptor Antagonists | 1 | 2011 | 7 | 0.020 |
Why?
| | Health Policy | 1 | 2012 | 160 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2011 | 54 | 0.020 |
Why?
| | Adrenergic beta-Agonists | 1 | 1991 | 42 | 0.020 |
Why?
| | Goals | 1 | 1991 | 46 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2012 | 173 | 0.020 |
Why?
| | Recovery of Function | 1 | 2012 | 201 | 0.020 |
Why?
| | Mannitol | 1 | 1990 | 15 | 0.020 |
Why?
| | Critical Care | 1 | 2012 | 218 | 0.020 |
Why?
| | Dopamine | 1 | 1991 | 169 | 0.020 |
Why?
| | Body Water | 1 | 1990 | 27 | 0.020 |
Why?
| | Vasoconstriction | 1 | 1990 | 56 | 0.020 |
Why?
| | Blood Volume | 1 | 1990 | 63 | 0.020 |
Why?
| | Sodium | 1 | 1990 | 95 | 0.020 |
Why?
| | Program Development | 1 | 2011 | 165 | 0.020 |
Why?
| | Graft Survival | 1 | 1991 | 159 | 0.020 |
Why?
| | Adrenergic beta-2 Receptor Antagonists | 1 | 2009 | 1 | 0.020 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2009 | 5 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2009 | 151 | 0.020 |
Why?
| | Lymphocytes | 1 | 1990 | 148 | 0.020 |
Why?
| | Isoquinolines | 1 | 2008 | 24 | 0.020 |
Why?
| | Cell Death | 1 | 2009 | 175 | 0.020 |
Why?
| | Serine | 1 | 2008 | 35 | 0.020 |
Why?
| | Tyrphostins | 1 | 2008 | 10 | 0.020 |
Why?
| | Janus Kinases | 1 | 2008 | 7 | 0.020 |
Why?
| | Physical Exertion | 1 | 1988 | 46 | 0.020 |
Why?
| | Selection Bias | 1 | 2008 | 15 | 0.020 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2008 | 74 | 0.020 |
Why?
| | Pulse | 1 | 1988 | 13 | 0.020 |
Why?
| | Pennsylvania | 3 | 1993 | 34 | 0.020 |
Why?
| | Ischemic Preconditioning, Myocardial | 1 | 2007 | 2 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2008 | 269 | 0.020 |
Why?
| | Organ Culture Techniques | 1 | 2007 | 44 | 0.020 |
Why?
| | Creatine Kinase, BB Form | 1 | 2007 | 1 | 0.020 |
Why?
| | Receptors, Purinergic P1 | 1 | 2007 | 7 | 0.020 |
Why?
| | Bayes Theorem | 1 | 1988 | 120 | 0.020 |
Why?
| | Survival | 1 | 2007 | 12 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2008 | 117 | 0.020 |
Why?
| | Theophylline | 1 | 2007 | 18 | 0.020 |
Why?
| | Pyridazines | 1 | 1987 | 10 | 0.020 |
Why?
| | 5'-Nucleotidase | 1 | 2007 | 12 | 0.020 |
Why?
| | Nitriles | 1 | 2007 | 51 | 0.020 |
Why?
| | Pain | 2 | 1982 | 359 | 0.020 |
Why?
| | Blood Coagulation | 1 | 2007 | 62 | 0.020 |
Why?
| | Bundle-Branch Block | 1 | 1987 | 19 | 0.020 |
Why?
| | Models, Chemical | 1 | 2007 | 66 | 0.020 |
Why?
| | Premedication | 1 | 2007 | 17 | 0.020 |
Why?
| | Evaluation Studies as Topic | 3 | 1992 | 105 | 0.020 |
Why?
| | Butadienes | 1 | 2007 | 49 | 0.020 |
Why?
| | Drug Combinations | 1 | 2007 | 134 | 0.020 |
Why?
| | Depression, Chemical | 1 | 1986 | 13 | 0.020 |
Why?
| | Coenzymes | 1 | 2006 | 3 | 0.020 |
Why?
| | Stimulation, Chemical | 1 | 1986 | 27 | 0.020 |
Why?
| | Vasoactive Intestinal Peptide | 1 | 1986 | 20 | 0.020 |
Why?
| | Amrinone | 1 | 1986 | 1 | 0.020 |
Why?
| | Heart Function Tests | 1 | 1986 | 12 | 0.020 |
Why?
| | Oncogene Protein v-akt | 1 | 2006 | 12 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2007 | 80 | 0.020 |
Why?
| | Educational Measurement | 1 | 2008 | 195 | 0.020 |
Why?
| | Receptors, Vasopressin | 1 | 2006 | 23 | 0.020 |
Why?
| | Phosphoric Monoester Hydrolases | 1 | 2006 | 23 | 0.020 |
Why?
| | Alanine | 1 | 2006 | 43 | 0.020 |
Why?
| | Amidines | 1 | 2006 | 6 | 0.020 |
Why?
| | Lactates | 1 | 1986 | 31 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2008 | 226 | 0.020 |
Why?
| | Benzylamines | 1 | 2006 | 14 | 0.020 |
Why?
| | Sulfones | 1 | 2006 | 24 | 0.020 |
Why?
| | PTEN Phosphohydrolase | 1 | 2006 | 55 | 0.020 |
Why?
| | Long-Term Care | 1 | 1986 | 51 | 0.020 |
Why?
| | Models, Animal | 1 | 2006 | 228 | 0.010 |
Why?
| | Research Design | 1 | 2008 | 372 | 0.010 |
Why?
| | Magnetic Resonance Angiography | 1 | 2006 | 67 | 0.010 |
Why?
| | Nitric Oxide | 1 | 2007 | 244 | 0.010 |
Why?
| | Heart Conduction System | 1 | 2005 | 25 | 0.010 |
Why?
| | Osmotic Pressure | 1 | 1985 | 12 | 0.010 |
Why?
| | Half-Life | 1 | 1985 | 87 | 0.010 |
Why?
| | Safety | 1 | 2005 | 80 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 1989 | 318 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1985 | 62 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2007 | 371 | 0.010 |
Why?
| | Aortography | 1 | 2004 | 33 | 0.010 |
Why?
| | Glyburide | 1 | 2004 | 5 | 0.010 |
Why?
| | Anastomosis, Surgical | 1 | 2004 | 69 | 0.010 |
Why?
| | Scleroderma, Systemic | 1 | 1984 | 6 | 0.010 |
Why?
| | Ventricular Fibrillation | 1 | 2004 | 17 | 0.010 |
Why?
| | Anesthesia, Obstetrical | 1 | 2004 | 39 | 0.010 |
Why?
| | Verapamil | 1 | 1984 | 20 | 0.010 |
Why?
| | Models, Biological | 1 | 2007 | 739 | 0.010 |
Why?
| | Vascular Surgical Procedures | 1 | 2006 | 166 | 0.010 |
Why?
| | Statistics as Topic | 1 | 2004 | 89 | 0.010 |
Why?
| | Patient Discharge | 1 | 2006 | 326 | 0.010 |
Why?
| | Transcription Factors | 1 | 2007 | 566 | 0.010 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2003 | 11 | 0.010 |
Why?
| | Cesarean Section | 1 | 2004 | 184 | 0.010 |
Why?
| | Pulmonary Artery | 1 | 1984 | 147 | 0.010 |
Why?
| | Swine | 1 | 2004 | 427 | 0.010 |
Why?
| | Endpoint Determination | 1 | 2002 | 27 | 0.010 |
Why?
| | Thorax | 1 | 1982 | 14 | 0.010 |
Why?
| | Anxiety Disorders | 1 | 1982 | 130 | 0.010 |
Why?
| | Popliteal Artery | 1 | 2000 | 28 | 0.010 |
Why?
| | Iliac Artery | 1 | 2000 | 31 | 0.010 |
Why?
| | Hospitals, University | 1 | 1999 | 75 | 0.010 |
Why?
| | Mortality | 1 | 1999 | 105 | 0.010 |
Why?
| | Brain | 1 | 2006 | 1322 | 0.010 |
Why?
| | Abdomen | 1 | 1977 | 73 | 0.010 |
Why?
| | Dyspnea | 1 | 1977 | 80 | 0.010 |
Why?
| | Pregnancy | 1 | 2004 | 2671 | 0.010 |
Why?
| | Physical Examination | 1 | 1977 | 99 | 0.010 |
Why?
| | Fatigue | 1 | 1977 | 129 | 0.010 |
Why?
| | Physical Fitness | 1 | 1997 | 57 | 0.010 |
Why?
| | Actuarial Analysis | 1 | 1996 | 9 | 0.010 |
Why?
| | Walking | 1 | 1997 | 106 | 0.010 |
Why?
| | Nitroprusside | 1 | 1992 | 11 | 0.010 |
Why?
| | Neck | 1 | 1993 | 98 | 0.010 |
Why?
| | Pilot Projects | 1 | 1995 | 722 | 0.010 |
Why?
| | Transplantation, Heterotopic | 1 | 1991 | 7 | 0.010 |
Why?
| | Regression Analysis | 1 | 1991 | 401 | 0.010 |
Why?
| | Cyclosporine | 1 | 1991 | 67 | 0.010 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1990 | 57 | 0.010 |
Why?
| | Histocompatibility Testing | 1 | 1990 | 14 | 0.010 |
Why?
| | Transplantation, Heterologous | 1 | 1989 | 78 | 0.000 |
Why?
| | Cell Division | 1 | 1990 | 290 | 0.000 |
Why?
| | Length of Stay | 1 | 1991 | 672 | 0.000 |
Why?
| | Bundle of His | 1 | 1987 | 7 | 0.000 |
Why?
| | Atrial Flutter | 1 | 1987 | 9 | 0.000 |
Why?
| | Phenotype | 1 | 1990 | 800 | 0.000 |
Why?
| | Cobalt | 1 | 1986 | 17 | 0.000 |
Why?
| | Histological Techniques | 1 | 1986 | 9 | 0.000 |
Why?
| | Endomyocardial Fibrosis | 1 | 1985 | 3 | 0.000 |
Why?
| | Doxorubicin | 1 | 1986 | 241 | 0.000 |
Why?
| | Thallium | 1 | 1984 | 6 | 0.000 |
Why?
| | Radioisotopes | 1 | 1984 | 17 | 0.000 |
Why?
| | Heart Defects, Congenital | 1 | 1990 | 615 | 0.000 |
Why?
| | Microcirculation | 1 | 1984 | 63 | 0.000 |
Why?
| | Radionuclide Imaging | 1 | 1984 | 107 | 0.000 |
Why?
| | Infant | 1 | 1990 | 3691 | 0.000 |
Why?
| | Child, Preschool | 1 | 1990 | 4034 | 0.000 |
Why?
| | Child | 1 | 1990 | 7194 | 0.000 |
Why?
|
|
Uretsky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|